Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICSAntonio Avallone, Maria Carmela Piccirillo, Antonio Cassata et al.|Annals of Oncology|2017Cited by 2
A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer (mCRC)A. Antonio, Federica Perrone, Maria Carmela Piccirillo et al.|Annals of Oncology|2016Cited by 0
A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)Antonio Avallone, Maria Carmela Piccirillo, Guglielmo Nasti et al.|Annals of Oncology|2017Cited by 0
Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)Antonio Avallone, Maria Carmela Piccirillo, Guglielmo Nasti et al.|Annals of Oncology|2018Cited by 0